NasdaqGS:INSMBiotechs
Should Insmed’s (INSM) Brensocatib Setback in Hidradenitis Suppurativa Require Action From Investors?
Insmed announced that its Phase 2b CEDAR study of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary or secondary efficacy endpoints, leading the company to halt development of the drug for this indication despite a clean safety profile.
An interesting outcome was that placebo patients saw a larger reduction in abscess and inflammatory nodule counts than either brensocatib dose, raising fresh questions about disease variability and trial design in...